JAN 25, 2018 01:37 PM PST

Therapeutic Antibody Inactivates Allergic Response

WRITTEN BY: Kara Marker

A new technique for treating allergies is on the way, and a therapeutic antibody is responsible. From Aarhus University, researchers introduce a novel antibody capable of inhibiting histamine production and an allergic reaction.

Obstruction and inflammation of the bronchiole characteristic of asthma. Credit: Yale Rosen

The single-domain, ultra-stable antibody prevents IgE, a human antibody associated with the allergic response in the immune system, from attaching to two cell receptors (CD23, FceRI). Normally, high levels of IgE are produced in response to exposure to allergens like pollen or insect venom. IgE antibodies attach to effector immune cells and produce histamine, which is the key ingredient for an allergic response.

But the therapeutic antibody Aarhus University researchers used in their studies thwarts the activity of IgE, blocking the allergic response that begins in the immune system. Additionally, the antibody is capable of removing IgE molecules after binding CD23 and FceRI.

“It doesn't matter that the body produces millions of allergen-specific IgE molecules,” explained Aarhus University’s Edzard Spillner. “When we can remove the trigger, the allergic reaction and symptoms will not occur.”

Interestingly enough, the new antibody is effective despite being smaller than therapeutic antibodies currently used in pharmaceutical products for allergy relief. Plus, its chemical structure allows it to be inhaled or swallowed, while many antibody-based allergy treatments available need to be injected.

The interaction between the experimental antibody and IgE has been tested in the lab with blood cells from people allergic to pollen and venom. Researchers believe it is applicable to other allergens and asthma as well.

Spillner and others are hoping to use this discovery to develop more effective treatments for allergies of all kinds.

"We can now precisely map how the antibody prevents binding of IgE to its receptors,” said Nick Laursen. “This allows us to envision completely new strategies for engineering medicine of the future.”

Experts at the Asthma and Allergy Foundation of America estimate that nasal allergies alone impact more than 50 million people in the United States, and that number continues to increase.

Before an allergy treatment with the new antibody as its main ingredient can become available to the public, Spillner, Laursen, and the other researchers from Aarhus University will have to conduct many clinical trials to ensure its efficacy and safety.

The present study was published in the journal Nature Communications.

Source: Aarhus University

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
MAY 17, 2018
Immunology
MAY 17, 2018
Epigenetic Similarities Between Rheumatoid Arthritis and Huntington's Disease
A detailed investigation into the epigenome of rheumatoid arthritis (RA) patients revealed unexpected similarities between RA and Huntington’s diseas...
JUN 12, 2018
Immunology
JUN 12, 2018
Auto-antibody Detection for Rheumatoid Arthritis Patients
No case of rheumatoid arthritis (RA), an autoimmune disease, is the same. Now, researchers want RA diagnostic approaches to match its pathological diversit...
JUL 11, 2018
Immunology
JUL 11, 2018
The Power of Seal Serum
Unlike humans, seals remain uninjured despite repeated deep dives to hunt. Scientists have shown that serum from seals blood provides anti-inflammatory properties that lower immune response....
JUL 15, 2018
Immunology
JUL 15, 2018
Enzyme Pathway Mediates Immune Response to Chagas Disease
The enzyme, PI3Kγ, regulates the immune response to T. cruzi, the cause of Chagas Disease. Manipulation of this enzyme may lead to better treatment of T. cruzi....
AUG 28, 2018
Drug Discovery
AUG 28, 2018
Combination Therapy for Advanced Melonoma
According to a research study led by UCLA, a bacteria-like agent used in combination with an immunotherapeutic drug may help patients survive longer with a...
SEP 11, 2018
Immunology
SEP 11, 2018
Oops! I Broke My DNA
Innate Immune System, DNA Damage and Repair...
Loading Comments...